Contineum Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Contineum Therapeutics, Inc. (CTNM) had Debt Securities, Available-for-sale, Amortized Cost of $187.03 million as of 2025-12-31, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-30
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $187.03M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $139.51M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $154.55M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $168.07M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-12-31 | $187.03M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $139.51M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $154.55M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $168.07M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $182.75M 10-K · filed 2026-03-05 |
| 2024-09-30 | $172.46M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $141.55M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $101.70M 10-Q · filed 2024-05-16 |
| 2023-12-31 | $109.55M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |